Soleno Therapeutics Receives FDA Extension for DCCR Review
Soleno Therapeutics, Inc. made public on November 26, 2024, that the U.S. Food and Drug Administration (FDA) has lengthened the review period for the New Drug Application (NDA) concerning DCCR (diazoxide choline) extended-release tablets. Initially set for December 27, 2024, the new target action date for this review is now March 27, 2025. The extension ...
Publicado el: 2024-11-28 07:00:54
Autor: MarketBeat News, Fuente: etfdailynews
Compartir: 
